Skip Nav Destination
Issues
15 November 2017
-
Cover Image
Cover Image
The cover shows a section of a MET-amplified patient-derived xenograft analyzed by MET:GRB2 proximity ligation assay. Analysis of MET:GRB2 signaling-associated complexes may help predict response to MET tyrosine kinase inhbitors. For details, see the article by Smith and colleagues on page 7084 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Drug Updates
Review
Cancer Therapy: Clinical
Author Choice
Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer
Martin Scurr; Tom Pembroke; Anja Bloom; David Roberts; Amanda Thomson; Kathryn Smart; Hayley Bridgeman; Richard Adams; Alison Brewster; Robert Jones; Sarah Gwynne; Daniel Blount; Richard Harrop; Robert Hills; Awen Gallimore; Andrew Godkin
Author Choice
Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance
Linda S. Nooij; Natalja T. ter Haar; Dina Ruano; Natalia Rakislova; Tom van Wezel; Vincent T.H.B.M. Smit; Baptist J.B.M.Z. Trimbos; Jaume Ordi; Mariette I.E. van Poelgeest; Tjalling Bosse
Author Choice
Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers
Michal Abraham; Yaron Pereg; Baruch Bulvik; Shiri Klein; Inbal Mishalian; Hana Wald; Orly Eizenberg; Katia Beider; Arnon Nagler; Rottem Golan; Abi Vainstein; Arnon Aharon; Eithan Galun; Yoseph Caraco; Reuven Or; Amnon Peled
Author Choice
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
Himisha Beltran; Alexander W. Wyatt; Edmund C. Chedgy; Adam Donoghue; Matti Annala; Evan W. Warner; Kevin Beja; Michael Sigouros; Fan Mo; Ladan Fazli; Colin C. Collins; James Eastham; Michael Morris; Mary-Ellen Taplin; Andrea Sboner; Susan Halabi; Martin E. Gleave
Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide
Carla Calagua; Joshua Russo; Yue Sun; Rachel Schaefer; Rosina Lis; Zhenwei Zhang; Kathleen Mahoney; Glenn J. Bubley; Massimo Loda; Mary-Ellen Taplin; Steven P. Balk; Huihui Ye
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer
Cynthia X. Ma; Vera Suman; Matthew P. Goetz; Donald Northfelt; Mark E. Burkard; Foluso Ademuyiwa; Michael Naughton; Julie Margenthaler; Rebecca Aft; Richard Gray; Amye Tevaarwerk; Lee Wilke; Tufia Haddad; Timothy Moynihan; Charles Loprinzi; Tina Hieken; Erica K. Barnell; Zachary L. Skidmore; Yan-Yang Feng; Kilannin Krysiak; Jeremy Hoog; Zhanfang Guo; Leslie Nehring; Kari B. Wisinski; Elaine Mardis; Ian S. Hagemann; Kiran Vij; Souzan Sanati; Hussam Al-Kateb; Obi L. Griffith; Malachi Griffith; Laurence Doyle; Charles Erlichman; Matthew J. Ellis
Author Choice
Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury
Christopher R. Heery; Claudia Palena; Sheri McMahon; Renee N. Donahue; Lauren M. Lepone; Italia Grenga; Ulrike Dirmeier; Lisa Cordes; Jenn Marté; William Dahut; Harpreet Singh; Ravi A. Madan; Romaine I. Fernando; Duane H. Hamilton; Jeffrey Schlom; James L. Gulley
Author Choice
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Jörg Felsberg; for the German Glioma Network; Bettina Hentschel; for the German Glioma Network; Kerstin Kaulich; for the German Glioma Network; Dorothee Gramatzki; for the German Glioma Network; Angela Zacher; for the German Glioma Network; Bastian Malzkorn; for the German Glioma Network; Marcel Kamp; for the German Glioma Network; Michael Sabel; for the German Glioma Network; Matthias Simon; for the German Glioma Network; Manfred Westphal; for the German Glioma Network; Gabriele Schackert; for the German Glioma Network; Jörg C. Tonn; for the German Glioma Network; Torsten Pietsch; for the German Glioma Network; Andreas von Deimling; for the German Glioma Network; Markus Loeffler; for the German Glioma Network; Guido Reifenberger; for the German Glioma Network; Michael Weller; for the German Glioma Network
Personalized Medicine and Imaging
MSH2 Loss in Primary Prostate Cancer
Liana B. Guedes; Emmanuel S. Antonarakis; Michael T. Schweizer; Nooshin Mirkheshti; Fawaz Almutairi; Jong Chul Park; Stephanie Glavaris; Jessica Hicks; Mario A. Eisenberger; Angelo M. De Marzo; Jonathan I. Epstein; William B. Isaacs; James R. Eshleman; Colin C. Pritchard; Tamara L. Lotan
Cancer Therapy: Preclinical
Author Choice
Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
Yan Kong; Xinan Sheng; Xiaowen Wu; Junya Yan; Meng Ma; Jiayi Yu; Lu Si; Zhihong Chi; Chuanliang Cui; Jie Dai; Yiqian Li; Huan Yu; Tianxiao Xu; Huan Tang; Bixia Tang; Lili Mao; Bin Lian; Xuan Wang; Xieqiao Yan; Siming Li; Jun Guo
Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms
Inan Olmez; Breanna Brenneman; Aizhen Xiao; Vlad Serbulea; Mouadh Benamar; Ying Zhang; Laryssa Manigat; Tarek Abbas; Jeongwu Lee; Ichiro Nakano; Jakub Godlewski; Agnieszka Bronisz; Roger Abounader; Norbert Leitinger; Benjamin Purow
Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage in Genetics and Glucocorticoid Sensitivity
Laura Simon; Vincent-Philippe Lavallée; Marie-Eve Bordeleau; Jana Krosl; Irène Baccelli; Geneviève Boucher; Bernhard Lehnertz; Jalila Chagraoui; Tara MacRae; Réjean Ruel; Yves Chantigny; Sébastien Lemieux; Anne Marinier; Josée Hébert; Guy Sauvageau
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
MohammadA Sabbaghi; Gabriel Gil-Gómez; Cristina Guardia; Sonia Servitja; Oriol Arpí; Sara García-Alonso; Silvia Menendez; Montserrat Arumi-Uria; Laia Serrano; Marta Salido; Aura Muntasell; Maria Martínez-García; Sandra Zazo; Cristina Chamizo; Paula González-Alonso; Juan Madoz-Gúrpide; Pilar Eroles; Joaquin Arribas; Ignasi Tusquets; Ana Lluch; Atanasio Pandiella; Federico Rojo; Ana Rovira; Joan Albanell
Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice
Marina Pajic; Sohvi Blatter; Charlotte Guyader; Maaike Gonggrijp; Ariena Kersbergen; Aslι Küçükosmanoğlu; Wendy Sol; Rinske Drost; Jos Jonkers; Piet Borst; Sven Rottenberg
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
Heather J. Dalton; Sunila Pradeep; Michael McGuire; Yared Hailemichael; Shaolin MA; Yasmin Lyons; Guillermo N. Armaiz-Pena; Rebecca A. Previs; Jean Marie Hansen; Rajesha Rupaimoole; Vianey Gonzalez-Villasana; Min Soon Cho; Sherry Y. Wu; Lingegowda S. Mangala; Nicholas B. Jennings; Wei Hu; Robert Langley; Hong Mu; Michael Andreeff; Menashe Bar-Eli; Willem Overwijk; Prahlad Ram; Gabriel Lopez-Berestein; Robert L. Coleman; Anil K. Sood
Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas
Sung Hugh Choi; Daniel W. Stuckey; Sara Pignatta; Clemens Reinshagen; Jasneet Kaur Khalsa; Nicolaas Roozendaal; Jordi Martinez-Quintanilla; Kaoru Tamura; Erhan Keles; Khalid Shah
Biology of Human Tumors
Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival
Gaëlle Müller-Greven; Cathleen R. Carlin; Monica E. Burgett; Manmeet S. Ahluwalia; Adam Lauko; Amy S. Nowacki; Cameron J. Herting; Maha A. Qadan; Markus Bredel; Steven A. Toms; Justin D. Lathia; Dolores Hambardzumyan; Jann N. Sarkaria; Petra Hamerlik; Candece L. Gladson
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup
David P. Labbé; Christopher J. Sweeney; Myles Brown; Phillip Galbo; Spencer Rosario; Kristine M. Wadosky; Sheng-Yu Ku; Martin Sjöström; Mohammed Alshalalfa; Nicholas Erho; Elai Davicioni; R. Jeffrey Karnes; Edward M. Schaeffer; Robert B. Jenkins; Robert B. Den; Ashley E. Ross; Michaela Bowden; Ying Huang; Kathryn P. Gray; Felix Y. Feng; Daniel E. Spratt; David W. Goodrich; Kevin H. Eng; Leigh Ellis
MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors
Matthew A. Smith; Thomas Licata; Aliya Lakhani; Marileila Varella Garcia; Hans-Ulrich Schildhaus; Vincent Vuaroqueaux; Balazs Halmos; Alain C. Borczuk; Y. Ann Chen; Benjamin C. Creelan; Theresa A. Boyle; Eric B. Haura
MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma
Marie Ennen; Céline Keime; Giovanni Gambi; Alice Kieny; Sebastien Coassolo; Christelle Thibault-Carpentier; Fanny Margerin-Schaller; Guillaume Davidson; Constance Vagne; Dan Lipsker; Irwin Davidson
Author Choice
Downregulation of SAFB Sustains the NF-κB Pathway by Targeting TAK1 during the Progression of Colorectal Cancer
Hong-Li Jiao; Ya-Ping Ye; Run-Wei Yang; Hui-Ying Sun; Shu-Yang Wang; Yong-Xia Wang; Zhi-Yuan Xiao; Liu-Qing He; Juan-Juan Cai; Wen-Ting Wei; Yan-Ru Chen; Chun-Cai Gu; Yue-Long Cai; Yun-Teng Hu; Qiu-Hua Lai; Jun-Feng Qiu; Li Liang; Guang-Wen Cao; Wen-Ting Liao; Yan-Qing Ding
Antagonism of EG-VEGF Receptors as Targeted Therapy for Choriocarcinoma Progression In Vitro and In Vivo
Wael Traboulsi; Frédéric Sergent; Houssine Boufettal; Sophie Brouillet; Rima Slim; Pascale Hoffmann; Mohammed Benlahfid; Qun Y. Zhou; Gianfranco Balboni; Valentina Onnis; Pierre A. Bolze; Aude Salomon; Philippe Sauthier; François Mallet; Touria Aboussaouira; Jean J. Feige; Mohamed Benharouga; Nadia Alfaidy
A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA
Akira Ooki; Zahra Maleki; Jun-Chieh J. Tsay; Chandra Goparaju; Mariana Brait; Nitesh Turaga; Hae-Seong Nam; William N. Rom; Harvey I. Pass; David Sidransky; Rafael Guerrero-Preston; Mohammad Obaidul Hoque
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds